Lv1
40 积分 2024-07-04 加入
Prediction of treatment response in drug-naïve schizophrenia patients from the perspective of targeted metabolomics
9天前
已完结
Metabolic profiling identifies TC and LDL as potential serum biomarkers for depressive symptoms in schizophrenia
8个月前
已完结
Metabolomics: A Powerful Tool to Understand the Schizophrenia Biology
8个月前
已完结
The Relationship between Alterations in Plasma Metabolites and Treatment Responses in Antipsychotic-Naïve Female Patients with Schizophrenia
8个月前
已完结
Potential plasma biomarker panels identification for the diagnosis of first-episode schizophrenia and monitoring antipsychotic monotherapy with the use of metabolomics analyses
8个月前
已完结
Plasma linoelaidyl carnitine levels positively correlated with symptom improvement in olanzapine-treated first-episode drug-naïve schizophrenia
8个月前
已完结
Metabolic profiling identifies TC and LDL as potential serum biomarkers for depressive symptoms in schizophrenia
8个月前
已完结
Metabolomics-based understanding of the olanzapine-induced weight gain in female first-episode drug-naïve patients with schizophrenia
8个月前
已完结
Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System
9个月前
已完结
Alopecia associated with the use of semaglutide and tirzepatide: A disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023
9个月前
已完结
皖公网安备34019202002308
